- NASDAQ: VBIV is set to surge to the highest levels in a month.
- Enthusiasm over VBI Vaccines Inc's potent pan-coronavirus immunization candidate is driving shares higher.
- In a highly competitive race for COVID-19 vaccines, quality may mark a difference.
Vaccinating against more than one coronavirus – and doing it better than competitors – is what VBI Vaccines is seeking. The Massachusets-based pharma firm has performed several preclinical trials on mice and claims that they have provoked a substantial creation of antibodies and other mechanisms to defend against coronaviruses.
The use of the plural is no mistake – one of the candidates is a "trivalent" pan-coronavirus vaccine, protecting against the raging SARS-Cov-2, the 2003-era SARS-CoV, and also MERS-CoV, which dates back to 2015.
Another advantage is that VBI's vaccine may require only one shot – allowing faster distribution of immunization to the world population.
Skeptics have noted that optimism in the preclinical stage may not necessarily translate into success with human subjects. Moreover, several large pharma firms are already conducting Phase 3 tests – injecting their solutions to around 30,000 subjects.
Nevertheless, the AstraZeneca/University of Oxford project – considered the most advanced – may work for only 12-24 months. With dozens of companies working on a solution – and limited production capacity – there is still time for smaller firms to provide potentially better solutions.
The high level of antibodies created – at least among mice – may be a differentiating factor. That has led Steven Seedhouse, an analyst with Raymond James, to upgrade the stock to "strong-buy", adding that "VBI may be in an entirely different ballpark for potency vs. any other vaccine we've seen."
VBIV Stock Forecast
NASDAQ: VBIV is quoted at around $4.50 in Friday's pre-market trading, building on top of its whopping 32% leap on Thursday. VBI Vaccines is on course to hit the highest since late July, a one-month high. The 52-week high of $6.83 is the bullish upside target. Support awaits at $3.19, August's low.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
USD/JPY pops and drops on BoJ's expected hold
USD/JPY reverses a knee-jerk spike to 142.80 and returns to the red below 142.50 after the Bank of Japan announced on Friday that it maintained the short-term rate target in the range of 0.15%-0.25%, as widely expected. Governor Ueda's press conference is next in focus.
AUD/USD bears attack 0.6800 amid PBOC's status-quo, cautious mood
AUD/USD attacks 0.6800 in Friday's Asian trading, extending its gradual retreat after the PBOC unexpectedly left mortgage lending rates unchanged in September. A cautious market mood also adds to the weight on the Aussie. Fedspeak eyed.
Gold consolidates near record high, bullish potential seems intact
Gold price regained positive traction on Thursday and rallied back closer to the all-time peak touched the previous day in reaction to the Federal Reserve's decision to start the policy easing cycle with an oversized rate cut.
Ethereum rallies over 6% following decision to split Pectra upgrade into two phases
In its Consensus Layer Call on Thursday, Ethereum developers decided to split the upcoming Pectra upgrade into two batches. The decision follows concerns about potential risks in shipping the previously approved series of Ethereum improvement proposals.
Bank of Japan set to keep rates on hold after July’s hike shocked markets
The Bank of Japan is expected to keep its short-term interest rate target between 0.15% and 0.25% on Friday, following the conclusion of its two-day monetary policy review. The decision is set to be announced during the early Asian session.
Moneta Markets review 2024: All you need to know
VERIFIED In this review, the FXStreet team provides an independent and thorough analysis based on direct testing and real experiences with Moneta Markets – an excellent broker for novice to intermediate forex traders who want to broaden their knowledge base.